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This Recommendation was prepared by the EU Reference Laboratory for Alternatives to Animal Testing 
(EURL ECVAM), part of the Institute for Health and Consumer Protection (IHCP), Directorate-General 
Joint Research Centre (DG JRC) of the European Commission. 
 
The Recommendation was drafted on the basis of the ESAC Opinion and ESAC Working Group Report 
summarising the detailed scientific peer review of the Hadano-coordinated validation study of the Cell 
Transformation Assay based on the Bhas 42 cell line. The Recommendation further benefitted from 
comments and suggestions received from members of PARERE (EURL ECVAM's advisory body for 
Preliminary Assessment of Regulatory Relevance that brings together representatives of Member State 
regulatory bodies as well as EU agencies including ECHA, EFSA and EMA), and ESTAF (EURL ECVAM's 
Stakeholder Forum). Input was also provided by partner organisations of EURL ECVAM in the framework 
of the International Collaboration on Alternative Test Methods (ICATM), and via public commenting.  
 
Coordinator of the evaluation of the test submission was Raffaella Corvi. Coordinator of the ESAC Peer 
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BACKGROUND TO EURL ECVAM RECOMMENDATIONS 
The aim of a EURL ECVAM Recommendation is to provide EURL ECVAM views on the validity of the test 
method in question, to advise on possible regulatory applicability, limitations and proper scientific use 
of the test method, and to suggest possible follow-up activities in view of addressing knowledge gaps. 
During the development of its Recommendation, EURL ECVAM consults with its advisory body for 
Preliminary Assessment of Regulatory Relevance (PARERE) and the EURL ECVAM Stakeholder Forum 
(ESTAF). Moreover, EURL ECVAM consults with other Commission services and partner organisations of 
the International Cooperation on Alternative Test Methods (ICATM). Before finalising its 
Recommendations, EURL ECVAM also invites comments from the general public and, if applicable, from 







In 2012, Hadano Research Institute (HRI) Food and Drug Safety Center (FDSC) finalised a validation study 
on the Bhas 42 Cell Transformation Assay (CTA) for carcinogenicity testing, a short-term CTA using 
transfected BALB/c 3T3 cells. The study on the Bhas 42 CTA was performed using two similar test 
method protocols, which differ only in the plate design (6-well method and 96-well method) and the 
methodology of foci scoring. The study was financed by the New Energy and Industrial Technology 
Development Organisation (NEDO) in Japan and supervised by a Validation Management Team 
established by the Japanese Centre for the Validation of Alternative Methods (JaCVAM). At the request 
of JaCVAM, EURL ECVAM charged ESAC to review the Bhas 42 CTA validation study which finalised its 
review in December 2012. EURL ECVAM fully endorses the ESAC Opinion (Annex 1) on the overall 
performance of the Bhas 42 CTA 6-well and 96-well protocols and recommends the following: 
 
(1) Similar to previously validated in vitro CTAs (EC EURL ECVAM, 2012a), the Bhas 42 CTA aims at 
predicting the carcinogenic potential of chemicals. Based on the results of the validation study and 
other published data, both protocols (the 6-well and the 96-well methods) are considered 
sufficiently standardised, transferable, reproducible between laboratories and relevant to support 
the identification of potential carcinogenicity of substances. In addition, the Bhas 42 CTA may 
provide information on whether substances are tumour initiators or promoters. 
(2) Owing to the complexity of the mechanisms of tumour development and the intrinsic limitations of 
in vitro CTAs (e.g. reductionist in vitro model, limited metabolic capacity), Bhas 42 CTA should not 
be used as a stand-alone test method, but always in combination with other complementary 
information sources for the purposes of hazard assessment. A CTA should be used therefore as a 
component in a Weight of Evidence (WoE) approach or an Integrated Testing Strategy (ITS), 
including chemical category formation and read-across. 
(3) Depending on the regulatory context and the extent of other information available from non-
testing and testing approaches, it is conceivable that information on the transforming potential of 
chemicals generated by CTAs may be sufficient for decision-making and may thus in specific cases 
allow the waiving of the rodent bioassay. However, it should be noted that the use and relevance of 
CTA data may vary considerably from one sector to another. Therefore, like other CTAs (EC EURL 
ECVAM, 2012b), the Bhas 42 CTA could contribute to partial replacement and reduction of animal 
tests for hazard identification and risk assessment in the area of carcinogenicity, depending on 
other information sources available.  
(4) As the Bhas 42 CTA is based on a cell line and, therefore, no experimental animals are required for 
the preparation of the test system, it has additional benefits from a 3Rs perspective over other 
validated CTAs such as the SHE CTA, which is based on primary Syrian hamster embryonic cells (EC 
EURL ECVAM 2012a). 
(5) The 96-well format of the Bhas 42 CTA provides the possibility for the development of a high 
throughput version of this assay. To achieve this, automated imaging and scoring of transformed 
cells/foci needs to be established.  
(6) Since the Bhas 42 CTA can be considered as being reliable and relevant for assessing carcinogenic 




recommends that an OECD Test Guideline be developed comprising both the 6-well and 96-well 
plate versions of the protocol. 
(7) Respecting the provision of Directive 2010/63/EU (EU, 2010) on the protection of animals used for 
scientific purposes, before embarking on animal experiments to identify substances with 
carcinogenicity potential, data from Cell Transformation Assays should be considered in 
combination with complementary information in order to reduce and possibly avoid animal testing. 
Among different possible regulatory uses of CTAs, in the context of the REACH Regulation (in 
agreement with the provision of Annex XI point 1.2; EU, 2006), data from non-standard testing 
methods such as the Bhas 42 CTA or other CTAs (e.g. SHE CTA; EC EURL ECVAM 2012a), may be 







1. Introduction  
In order to assess the performance of CTAs for carcinogenicity assessment, the Organisation for 
Economic Cooperation and Development (OECD) finalised in 2007 a "Detailed Review Paper on Cell 
Transformation Assays for Detection of Chemical Carcinogens" (DRP31) (OECD, 2007). The DRP focused 
on the analysis of biological relevance, predictive capacity and reliability of the Syrian Hamster Embryo 
(SHE) assay, the BALB/c 3T3 assay and the C3H10T1/2 assay. The DRP31 concluded that a formal 
assessment of the assays, in particular focusing on development of standardised protocols would be 
important prior to the development of OECD Test Guidelines. Following the DRP31 recommendation, 
EURL ECVAM performed a study on the transferability and reliability of the SHE and BALB/c 3T3 assay 
protocols and issued an EURL ECVAM Recommendation in March 2012 (EC EURL ECVAM, 2012a) in 
which the development of an OECD Test Guideline of the SHE variants was recommended. This was 
based on the availability of sufficiently standardised protocols (as shown in the EURL ECVAM study), a 
satisfactory predictive capacity, and a broad and well described applicability domain (as summarised in 
DRP31). 
In addition to the assays covered by the DRP31, a short-term CTA using transfected BALB/c 3T3 cells 
(Bhas 42 CTA) has been developed and validated (Validation Study Report: Hayashi et al., 2012). The 
Bhas 42 CTA was applied to 98 chemicals including carcinogens and non-carcinogens and it was 
concluded that its performance for the prediction of chemical carcinogenicity is equivalent or superior 
to those of conventional genotoxicity assays. Also, it was shown that the assay is capable of detecting 
Ames-negative and Ames-discordant carcinogens in addition to Ames-positive carcinogens (Sakai et al., 
2010). The study on the Bhas 42 CTA was performed using two similar test method procedures which 
differ only in the plate design (one protocol based on 6-well micro-plates, the other one on 96-well 
micro-plates) and the methodology of foci scoring (Tanaka et al., 2009; Sakai et al., 2011; Hayashi et al., 
Validation Study Report). 
After completion of the study and finalisation of the validation study report in 2012 (EC EURLECVAM, 
2012a), EURL ECVAM requested the EURL ECVAM Scientific Advisory Committee (ESAC) at its meeting on 
6-7 November 2012 to peer-review the study (Validation Study Report: Hayashi et al.,2012) and to 
provide an ESAC Opinion (Annex 1), assisted through the establishment of an ESAC Working Group 
(WG). The ESAC WG report (EC EURL ECVAM, 2012b) and the ESAC Opinion were adopted by ESAC in 
December 2012. 
 
2. Test method definition 
The Bhas 42 CTA test method employs the Bhas 42 cell line as a test system. The Bhas 42 cells are 
available from the Japanese Collection of Research Bioresources (JCRB) Cell Bank at the National 
Institute of Biomedical Innovation (Osaka, Japan). Since the Bhas 42 cell line has been genetically 
modified, it should be noted that its use in the laboratory may be subject to country-specific 
authorisation provisions. 
Biological and mechanistic relevance of the test method 
Carcinogenesis is a complex multistage process by which normal cells are transformed into cancer cells 
characterised by an accumulation of changes at the cellular, genetic and epigenetic level (IARC, 2008). In 
vitro CTAs such as the Bhas 42 CTA have been shown to recapitulate a multistage process that closely 
models some stages of in vivo carcinogenesis. Cell transformation in all the systems studied to-date 
involves changes at each stage in order for progression to the next stage in the transformation process 




include (from primary to fully malignant cells): (1) a block in cellular differentiation, (2) acquisition of 
immortality, characterised by unlimited lifespan, an aneuploidy karyotype and a decreased genetic 
stability; (3) acquisition of tumorigenicity, which is closely associated with the in vitro phenotypes of foci 
formation, anchorage independent growth in semi-solid agar and autocrine growth factor production; 
and (4) full malignancy, including metastasis when the cells are injected into a suitable host, supporting 
the biological relevance of in vitro transformation to in vivo carcinogenicity (LeBoeuf et al., 1999). CTAs 
are to date the only optimised test methods that have the potential to detect both genotoxic and non-
genotoxic carcinogens in vitro as shown in the large body of evidence from empirical testing of a high 
number of chemicals of various chemical classes (DRP31, OECD 2007). 
The Bhas 42 cell line was developed from BALB/c 3T3 cells through transfection with a Harvey rat 
sarcoma viral mutated oncogene homolog (v-Ha-ras) (Sasaki et al., 1988; 1990). Since Ha-ras is strongly 
related to multi-step carcinogenesis, Bhas 42 cells are more predisposed to transformation than the 
original cells BALB/c 3T3. The assay was first developed by Ohmori et al. (2004) to identify tumour 
promoters. Subsequently, Asada et al. (2005) modified the Bhas 42 CTA protocol such that it was 
capable of detecting tumour initiating activity, as well as tumour promoting activity of chemicals.  
The current protocols consist of two assay components, the initiation assay and the promotion assay to 
detect the tumour-initiating and tumour-promoting activity of chemicals, respectively. In the initiation 
assay, the cells are inoculated at a low density and treated with test chemical in the beginning of the 
assay period so that the target cells can undergo cell division several times before reaching contact 
inhibition of growth, and thus DNA damage is fixed as mutations in the genes. In the promotion assay, 
the cells are seeded more densely than in the initiation assay and the treatment with a test chemical is 
started at sub-confluence and continued beyond confluence. A test chemical is positive (i.e. an in vitro 
cell transforming agent and hence considered a potential carcinogen) in the Bhas 42 CTA if the chemical 
is positive in one of the two assays, or in both. A negative result in both initiation and promoter assays 
suggest absence of transforming activity. 
Transformation by initiators (genotoxic carcinogens) is caused by accumulation of genetic alterations 
and generally it is considered that mutation in a single gene is not sufficient to result in transformation. 
This may explain why Bhas 42 cells, although they have undergone an initial step towards 
transformation, can still be transformed by genotoxic chemicals through the accumulation of genetic 
alterations in their genome.  
 
 
3. Overall performance of the CTA 
Level of standardisation of the test method 
It can be concluded from the HRI-coordinated study (Validation Study Report: Hayashi et al. 2012) that 
the protocols for both the 6-well and the 96-well variants of the method are transferable and 
reproducible between laboratories. Thus the current protocols are sufficiently well described and 
standardised to be recommended for routine use. EURL ECVAM will facilitate dissemination of the 
method protocols through its database on alternative methods (http://ecvam-dbalm.jrc.ec.europa.eu). 
These DB-ALM protocols will provide a comprehensive description of the method together with all the 
technical details needed by an end-user laboratory to implement it in a self-sufficient manner. The 







Reference data  
The validation of alternative methods aiming to predict human health effects relies on an element of 
calibration of the alternative method's predictive capacity on the basis of trusted reference data. These 
data are typically derived from animal studies believed to be relevant for the human situation due to 
their phylogenetic relatedness, biological similarity and systemic integrity. However, reference data 
derived from animals need to be interpreted with care: studies for various endpoints where human data 
are available have shown that animal tests are not always fully relevant for the human situation and are 
not always reproducible – which complicates the determination of unambiguous reference values 
associated with specific validation chemicals. Such limitations have been described in particular for the 
current standard model system for human carcinogenicity prediction, the cancer rodent (rat, mouse) 
bioassay (Gottmann et al., 2001; Haseman et al., 2001; Goodman, 2001; Ennever & Lave, 2003; Alden et 
al., 2011). This information should be kept in mind when evaluating the performance of alternative 
methods that have been calibrated to a large extent against these data. In a validation study the use of 
chemicals classified as clear human carcinogens would be ideal, however this becomes a bottleneck 
especially when selecting chemicals clearly classified as non-genotoxic carcinogens and non-carcinogens 
in human. The present study includes, among the rodent carcinogens, some chemicals classified as 
human carcinogens (IARC classes 1 and 2A). 
 
Reproducibility  
The two Bhas 42 CTA protocols yielded results that were concordant within and between laboratories 
and hence reproducible for the substances tested. This supports the view that the SOP appears to be 
sufficiently well-developed to allow the generation of reproducible results. 
Transferability 
The Bhas 42 CTA test method can be transferred to laboratories with sufficient expertise in cell culture. 
However, to ensure successful establishment of the test method in a naïve laboratory, it is strongly 
recommended that the standardised protocols be strictly followed and that sufficient training of 
operators be provided. Training on visual scoring of foci is particularly important for the 6-well protocol 
which depends on the precise quantification of foci, in contrast to the 96-well plate method protocol 
where an assessment of the absence or presence of (any number of) foci within a well is sufficient. 
Moreover, it is advised to make use of the photo-catalogue of transformed foci developed during the 
validation study when scoring (Hayashi et al., Validation Study Report). 
 
Predictive capacity 
The Bhas 42 CTA test method has the potential to support the detection of carcinogenic chemicals, 
including some non-genotoxic chemicals.  
For the 6-well assay (N=12 chemicals) the validation study demonstrated a 100% correlation of the 
predictions generated in vitro with the reference data generated by in vivo tests. In ten of the twelve 
cases all three labs agreed on the prediction ("call"), while in two cases two out of three labs made the 
correct prediction.  
The 96-well assay (N=21 chemicals) revealed an 86% concordance of in vitro versus in vivo predictions 




However, in one case, only 3 of the 4 labs characterised the chemical as negative (the “correct” 
prediction).  
Overall, these figures are in agreement with the published data on Bhas 42 performance (Sakai et al., 
2010). 
Although the method assay is useful for the detection of potential carcinogenicity in general, the 
performance characteristics of the Bhas 42 CTA test method for predicting tumour promoting activities 
of chemicals should be further evaluated, especially regarding the potential of the assay to discriminate 
between tumour initiators and promoters. While a study by Sakai et al. (2010) on 98 non-coded 
chemicals produced promising supporting results, the number of chemicals was considered too low to 
allow for definitive statements with respect to the capability of the assay to detect tumour promoters. 
Further assessment of the performance characteristics of the assay is desirable to understand the 
mechanism by which chemicals identified as carcinogens act. However, this uncertainty does not impact 







4. Applicability and limitations 
The following factors should be considered when implementing the Bhas 42 CTA method: 
 When using classes of chemicals different than those evaluated so far, it is recommended to verify 
applicability of the assay, for example by testing some chemicals of that class that have good 
reference data.  
 CTAs may be useful to test nanomaterials (Ponti et al. 2009) and particulates (Ohmori et al., 2013).  
 CTAs may be useful to test complex mixtures and formulations (Breheny et al. 2005; Weisensee et 
al., 2013).  
 As with many in vitro assays, the limited metabolic activity of the Bhas 42 cell line should be taken 
into account when interpreting results from the assay, in particular with regard to substances that 
are identified as negatives (i.e. non-carcinogenic). To address this in the future, the development of 
ITS should also include information sources that inform on potential biotransformation of the 
chemicals used.  
 The Bhas 42 CTA requires 3 weeks per substance. Although it can be considered a long-term in vitro 
assay it has a significantly higher throughput compared with the BALB/c 3T3 CTA that requires 6 
weeks and the cancer rodent bioassay that requires a minimum of 2 years.  
 
5. Suggested regulatory use  
The validation study showed that the Bhas 42 CTA is useful to detect carcinogenicity potential, rather 
than to specifically discriminate between initiators and promoters as it was initially developed for. 
Discrimination between genotoxic and non-genotoxic chemicals can be accomplished, however, if Bhas 
42 CTA is used in parallel with genotoxicity tests.  
Due to the complexity of the events leading to the final adverse effect and based on current scientific 
consensus, it is unlikely that a single in vitro method will provide sufficient information for an 
unequivocal assessment of the carcinogenicity potential of a substance to fully satisfy regulatory 
requirements. CTAs, such as the Bhas 42 CTA, may however provide useful information about possible 
genotoxic and non-genotoxic carcinogenicity potential for use in conjunction with other data to 
generate supporting information for hazard identification that can eventually contribute to the risk 
assessment. CTAs may thus be used for these purposes in the context of integrated approaches such as 
a Weight of Evidence (WoE) or Integrated Testing Strategies (ITS), including support for chemical 
category formation and read-across. 
Depending on the regulatory context and the extent of other information available from non-testing and 
testing approaches, it is conceivable that information on the transforming potential of chemicals 
generated by CTAs may be sufficient for decision-making and may thus in specific cases allow waiving of 
the rodent bioassay (OECD, 2009). In other cases, the CTA may provide testing data that still require 
confirmatory testing. Therefore, it is recommended that when a CTA is conducted, this should occur 
before embarking on a rodent bioassay. However, the use and relevance of CTA data may vary from one 
sector to another (Vanparys et al., 2012). For example, the data requirements but also the information 
already available will differ substantially between the pharmaceutical and cosmetics sectors (Sistare et 
al., 2011). 
Although the use of the CTA is not currently an explicit regulatory requirement in any regulatory area, its 




guidance on information requirements and chemical safety assessment for REACH (ECHA, 2012), the 
Scientific Committee on Consumer Safety (SCCS)'s guidance for the testing of cosmetic ingredients (SCCS 
2012), the guidance for testing cosmetics (Pfuhler et al., 2010), the EFSA opinion on a strategy for 
genotoxicity testing (EFSA, 2011), the US FDA guidance for integration of genetic toxicology study results 
for pharmaceuticals (FDA, 2006) and the ICH S1B Guideline on "Testing for Carcinogenicity of 
Pharmaceuticals" (ICH, 2009). In the context of REACH, in agreement with the provision of Annex XI 
point 1.2 of the REACH Regulation (EU, 2006) data from non-standard testing methods, such as the Bhas 
CTA or other CTAs (e.g. SHE CTA; EC EURL ECVAM 2012a), may be used to adapt the standard 
information requirements in the context of weight-of-evidence judgments. 
Recently, some tiered testing approaches which include the use of the CTAs have been reported 
(Benigni et al., 2013; Doktorova et al., 2012). 
Some current uses of the CTAs include:  
 to clarify the relevance of in vitro genotoxic positive results for prediction of carcinogenicity by 
weight of evidence (e.g. in chemical and cosmetics industries); 
 to evaluate certain classes of chemicals that have a low predictive capacity in the 
traditional in vitro genotoxicity tests (e.g. in chemical and cosmetic industries); 
 to screen for non-genotoxic carcinogens (e.g. in agro-chemical industry);  
 for read-across purposes (e.g. chemical industry);  
 in addition to the other available CTAs, the Bhas 42 CTA could be used in mechanistic studies of 
carcinogenicity to investigate tumour promotion activity (e.g. in the context of risk/safety 
assessments in agro-chemical and chemical industries, academia) and to discriminate between 
tumour initiators and promoters. However, some further work is required in view of assessing 
this potential use. 
Impact on 3Rs of the suggested regulatory use 
The Bhas 42 CTA has potential for regulatory use since the validation study undertaken has addressed 
and resolved a major regulatory concern, i.e. protocol standardisation. 
The use of cell line based CTAs, such as the Bhas 42 CTA, has the potential to lead to partial replacement 
and reduction of animal tests in the regulatory and non-regulatory context. In the regulatory assessment 
context, the results produced by the CTAs when combined with other suitable data may be sufficient to 
conclude on the absence or presence of a carcinogenic chemical hazard. It is conceivable too that in 
certain cases high quality CTA information may allow waiving the need to conduct the cancer bioassay.  
Therefore when used within integrated approaches, CTAs such as the Bhas 42 CTA have a potential 3Rs 
impact through partial replacement of the rodent bioassay. Moreover, the Bhas 42 CTA is more 






6. Follow-up activities recommended by EURL ECVAM  
(1) Preparation of a draft OECD Test Guideline (TG) including both the 6-well and 96-well 
standardised protocols to support the TG project already on the OECD work plan (lead country 
Japan). The use of the OECD TG may lead to the availability of additional high quality data to 
further explore the assay's applicability and predictive capacity, which may allow future 
revisions of the TG if necessary.  
(2) Development of conceptual frameworks to define optimal combinations of CTA data with 
complementary information sets to address carcinogenicity assessment specific to different 
sectorial needs. The intrinsic metabolic competence of the test system should also be taken into 
account when constructing such integrated approaches. 
(3) Checking the cell line stability, as part of good cell culture practice, should be continued in order 
to ensure the reliable and standardised use of the CTA.  
(4) Further investigations whether the Bhas 42 CTA is capable of detecting tumour promoting 
activity, not necessarily detected by genotoxicity assays, as indicated by published literature 
(Ohmori et al., 2004). This capability would provide useful information on mode of action of 
carcinogens for risk assessment purposes. 
(5) Promotion of further development in view of fully automating the 96-well plate protocol, 
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Summary of the ESAC Opinion 
The ESAC was requested to provide scientific advice to EURL ECVAM on two studies that 
JaCVAM had conducted in view of assessing whether the Bhas 42 CTA protocols (6-well plates 
and 96-well plates) have been sufficiently validated. Upon the data produced by this study, the 
ESAC concluded that the primary objectives of demonstrating transferability, reliability and 
relevance of the Bhas 42 Cell Transformation Assay (CTA) 6-well protocol and the Bhas 42 CTA 
96-well protocol were achieved.  
Secondary objectives of this were to assess whether the tests could identify non-genotoxic 
carcinogens and could discriminate between tumour initiating and tumour promoting (TP) 
compounds. This goal was not fully met because of difficulties in adequately defining the 
categories; however this difficulty is not unique to the Bhas 42 CTA . Both variations of the test 
did appear useful in detecting carcinogenic chemicals (including some non-genotoxic chemicals). 
While the advantages and potential of these tests were recognized, a number of issues were 
identified that weakened the statements made by the VMT. These issues were primarily related 
to the study design; however, they are not expected to change the overall qualifications of the 
tests in terms of WLR, transferability, BLR and predictive capacity.  
In spite of the differences between the applied scoring strategies, both CTA protocols were 
considered sufficiently standardized for assessing the cell transforming capacity of chemicals, 
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and these Bhas 42 protocols are suggested to be developed as the basis for an OECD Test 
Guideline on in vitro carcinogenicity testing.  
The ESAC recommends focusing on the preparation of an OECD Test Guideline based on general 
ability to induce Bhas 42 cell transformation, as part of a toolbox to be used for the 
identification of carcinogens.  
 
1. Mandate of the ESAC 
The ESAC Working Group (EWG) was requested to conduct a scientific peer review of the Bhas 
42 CTA Validation Management Team (VMT) report.  
The ESAC was requested to address the following three questions (see Annex 2, ECVAM Request 
for ESAC advice): 
1. To review whether the study of the Bhas 42 CTAs was conducted appropriately in 
view of the stated purpose, i.e. of assessing the CTA test method as a scientific valid 
method.  
2. To assess whether the conclusions as presented in the Study Report are justified by 
the information generated during the study. 
3. To express its opinion whether the CTA protocols are well standardized and could 
indeed be recommended to serve as a basis for an OECD Test Guideline on in vitro 
carcinogenicity testing 
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2. Detailed opinion of the ESAC 
2.1. The study of the Bhas 42 CTAs was conducted appropriately in view of the stated 
purpose, i.e. assessing the CTA test method as a scientific valid method 
Clarity of the definition of the study objectives. 
The primary objective was clearly defined as attempting to demonstrate the transferability, 
reliability (reproducibility within and between laboratories) and relevance (predictive capacity) 
of this test system using a set of coded chemicals whose carcinogenicities are known in vivo. 
The secondary objective is to demonstrate the utility of the test for adoption as an OECD TG 
that:  
 can detect genotoxic and non-genotoxic carcinogens; 
 is sensitive to TP; 
 can discriminate tumor-initiating and tumor-promoting activity of carcinogens.  
 
Appropriateness of the study design (e.g. chemical selection, number of chemicals used, number 
of laboratories, acceptance criteria). 
The number of chemicals (6-well assay: 8 carcinogens (including TP), 4 non-carcinogens; 96-well 
assay: 12 carcinogens (including TP), 9 non-carcinogens) was acceptable for assessing the 
transferability and reliability of the test. While this study produced results supporting Sakai et 
al. (2010) (98 non-coded chemicals), the number of chemicals was considered too low to allow 
for strong statements with respect to predictive capacity. 
The transferability of the test to inexperienced laboratories was not convincingly proven 
because the laboratories which were involved in the transfer phase of the study already were 
experienced in conducting the traditional Balb/c CTA.  
The study design to demonstrate the utility of the test for adoption as an OECD TG that can:  
 can detect genotoxic and non-genotoxic carcinogens; 
 is sensitive to TP; 
 can discriminate tumor-initiating and tumor-promoting activity of carcinogens; 
 was insufficient in several ways. 
 There was no selection procedure described for genotoxic and non-genotoxic 
carcinogens;  
 none of the chemicals were unambiguously identified as genotoxic or non-genotoxic; 
the number of TP chemicals (N=3) was too low to demonstrate the capability of the test 
to discriminate tumor-initiating and tumor-promoting carcinogens. 
 The number of laboratories involved at any time in the project (≥ 3) was deemed 
sufficient. 
Appropriateness of the study execution (e.g. were there pre-defined acceptance criteria, were 
these respected? How were exceptions / deviations handled, e.g. retesting?) 
For the 6-well assay acceptance criteria were not described in the protocol. Instead, ‘’low 
transformation in the positive control and high transformation in the negative control’’ were set 
as criteria for repetition of the test. The acceptance criteria for the 96-well assay (including the 
cell growth assay) were clear and detailed. 
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In general the acceptance criteria were followed. However, two incomplete results were 
produced by the same laboratory for the 6-well assay. With respect to the 96-well assay, two 
incomplete results were observed. These were due to circumstances affecting compound dosing 
but beyond the control of the laboratories. 
 
Appropriateness of the statistical analysis as used in the protocols and for analysing 
reproducibility and predictive capacity. 
The statistical analysis is based upon a conservative approach that minimizes the number of 
false positive results. This approach is acceptable for identification of clear positive and negative 
compounds, but may be problematic for less unambiguous compounds. The approach is 
dependent on the number of doses used in the test, with increasing number of doses reducing 
the statistical significance of the differences between control and test doses. 
A minor criticism on the design of the study and one which could possibly affect the outcome of 
the statistical analysis is that controls are isolated on separate plates, increasing the risk that 
differences between treatments (representing individual doses and controls) are due to the 
conditions affecting each specific plate and not to the concentration of the compound. 
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2.2. The overall conclusions as presented in the Study Report are generally justified by the 
information generated during the study although issues were identified that weaken the 
strength of the conclusions. 
Qualitative discussion of the study results/deliverables achieved within the limits of this study: 
Clarity and completeness of the protocol(s). 
(See 2.b) 
Within laboratory reproducibility (WLR) 
Overall the results were concordant. A different statistical method was used depending on the 
protocol (6-well or 96-well) which may affect the identification of the weakly positive chemicals. 
In general the acceptance criteria were followed. However, incomplete results were produced 
by one laboratory for the 6-well assay. Two incomplete results observed for the 96-well assay 
were due to circumstances affecting compound dosing but beyond the control of the 
laboratories. 
Transferability 
Details of the training program for the 6-well assay were not provided in the report. The 
transferability of the test to a laboratory not previously experienced in CTA was not 
demonstrated. The WG considers the test to be transferable to laboratories with experience in 
cell culturing techniques. For the 96-well assay post-training data were presented, and these 
data were satisfactory. 
Between-laboratory reproducibility (BLR) 
The BLR of the 6-well assay was assessed on 12 chemicals (coded) by 3 laboratories. In 9/12 
(75%), concordant results (number of foci) were obtained. Caffeine gave incomplete data in one 
laboratory due to not compliance with the protocol. The two remaining laboratories produced 
concordant results. It is unclear why results for anthracene and o-toluidine were not 
reproducible. The results for the positive controls MCA and TPA range between 10 and 50 foci 
per well. It is not possible to determine from the information given the reason(s) for this spread. 
The BLR of the 96-well assay was assessed by comparing laboratory results within the validation 
study. Twenty-two chemicals were tested by 4-6 labs. Results for initiation, promotion and 
transformation were acceptable (>90% for each endpoint).  
Predictive capacity 
The predictive capacity of the assays was assessed by comparing the “transformation” results 
for each of the tested chemicals and comparing that to the reported carcinogenicity in vivo. In 
the vast majority of the cases, all the laboratories agreed on the “transformation” call, but in a 
few instances, noted below, the judgement of the majority of the laboratory calls was accepted 
for the comparison.  
For the 6-well assay (N=12 chemicals) this comparison resulted in 100% correlation. In 10 of the 
12 cases all three labs agreed on the call. However, for anthracene only2 of the 3 labs 
characterized it as negative (the “correct” call), and for o-toluidine only 2 of the 3 labs 
characterized it as positive (the “correct” call).  
The 96-well assay (N=21 chemicals) revealed an 86% concordance, 83% sensitivity and 89% 
specificity. In twenty of the cases all labs (n = 2–8) agreed on the call. However, for 
phenanthrene, only 3 of the 4 labs characterized it as negative (the “correct” call). For common 
chemicals between the 96-well assay and the 6-well assay, sodium arsenite and o-toluidine 
were negative in the 96-well assay, with transformed foci on the side of the wells not scored as 
prescribed by the scoring criteria. Thus the 96-well method seems to need more investigation of 
scoring before the protocol is finalized. 
 
The conclusions presented in the study report are endorsed by the EWG with minor 
modifications. 
Clarity and completeness of the protocol(s) 
The protocol for the 6-well assay lacks sufficient technical detail, while the protocol for the 96-
well assay was more detailed. It is the ESAC WGs opinion that a lack of sufficient detail provided 
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in the scoring atlas may have contributed to the observed differences in the foci scored 
between experiments and laboratories. 
Within laboratory reproducibility (WLR) 
As concluded by the VMT, the within-laboratory reproducibility was shown to be satisfactory in 
all laboratories for the vehicle controls, the positive controls and for the test chemicals.  
Transferability 
The report did not include a detailed training program, the data produced during training or the 
quality of these data. Post-training data were only presented for the 96-well assay, and these 
data were satisfactory. 
The transferability of the test to a laboratory not previously experienced in CTA was not 
demonstrated.  The WG considers the test to be transferable to laboratories with experience in 
cell culturing techniques, but it requires more than one day of training. Considerable training in 
scoring of foci (and the use of the catalogue) might be required, especially for the 6-well assay. 
The value of the catalogue could be enhanced with description phrases. 
Between-laboratory reproducibility (BLR) 
The BLR of the 6-well assay was assessed on 12 chemicals (coded) by 3 laboratories. In 9/12 
(75%), concordant results were obtained. Caffeine gave incomplete data in one laboratory due 
to a lack of compliance with the protocol. The two remaining laboratories produced concordant 
results. It is unclear why results for anthracene and o-toluidine were not reproducible, although 
an answer could likely be determined if a re-evaluation of the foci was conducted. The values 
for MCA and TPA in the participating laboratories ranged from 10 to 50 foci per well which was 
considered a wide variation. It is not possible to determine from the information provided the 
reason(s) for this spread. The BLR (20 coded chemicals tested by 4-6 labs) of the 96-well assay 
was assessed by comparing laboratory results within the validation study. Results for both 
initiation and promotion were acceptable (95% for initiation and 85% promotion).  
A high level of between-laboratory reproducibility was demonstrated for both assays. However, 
significant quantitative differences (number of foci counted) between laboratories were 
observed for the positive control of the 6-well assay. It is unclear how these differences would 
affect the detection of chemicals of low potency. 
Predictive capacity 
The predictive capacity of the assays was assessed by comparing the “transformation” results 
for each of the tested chemicals and comparing that to the reported carcinogenicity in vivo. In 
the vast majority of the cases, all the laboratories agreed on the “transformation” call, but in a 
few instances, noted below, the judgement of the majority of the laboratory calls was accepted 
for the comparison. For the 6-well assay (N=12 chemicals) this comparison resulted in 100% 
correlation. In ten of the twelve cases all three labs agreed on the call. However, for anthracene, 
only 2 of the 3 labs characterized it as negative (the “correct” call), and for o-toluidine only 2 of 
the 3 labs characterized it as positive (the “correct” call). The 96-well assay (N=21 chemicals) 
revealed a 86% concordance, 83% sensitivity and 89% specificity. In twenty of the cases all labs 
(n = 2 – 8) agreed on the call. However, for phenanthrene, only 3 of the 4 labs characterized it as 
negative (the “correct” call).For common chemicals between the 96-well assay and the 6-well 
assay, sodium arsenite and o-toluidine were negative in the 96-well assay, with transformed foci 
on the side of the wells not scored as prescribed by the scoring criteria. Thus the 96-well 
method seems to need more investigation of scoring before the protocol is finalized. While this 
study produced promising results supporting Sakai et al. (2010) (98 non-coded chemicals), the 
number of chemicals was considered too low to allow for strong statements with respect to its 
predictive capacity. 
  




3. The CTA protocols were sufficiently standardized in the proposed protocol and could be 
recommended to serve as a basis for an OECD Test Guideline on in vitro carcinogenicity 
testing  
a). In spite of the differences between the applied scoring strategies, both CTA protocols were 
considered sufficiently standardized for assessing the cell transforming capacity of chemicals, 
and could be recommended to serve as a basis for an OECD Test Guideline on in vitro 
carcinogenicity testing, in line with the Balb/c 3T3 and SHE CTAs.  
It is however recommended to focus on the preparation of an OECD guideline based on general 
ability to induce Bhas 42 cell transformation, as part of a tool box to be used for cancer risk 
assessment. 
b). Other Issues 
Critical issues: 
1. There was no clear definition provided in the report for genotoxic and non-genotoxic 
carcinogens.  
2. Presentation of the assays for identification of genotoxic and non-genotoxic carcinogens 
should be reconsidered until a more systematic review of the genotoxicity and non-genotoxicity 
of tested compounds is conducted. 
3. Compounds with TP activity were few and not well defined. 
4. Scoring of foci is critical and the scoring atlas could be improved with textual descriptions of 
the reasons foci are described as transformed or not. 
5. The transferability of the test to a laboratory not previously experienced in CTA is not known.  
Gap analysis: 
The extent to which discordant results (e.g. o-toluidine) are due to scoring issues in the study is 
still not known. This should be clarified by a systematic re-evaluation of the existing plates. 
Lack of compounds with clear ‘initiator’ and ‘promoter’ activity makes it impossible to evaluate 
the capacity of the tests to discriminate between both sets of chemicals. 
 
3. Informative background to the Mandate and Opinion 
The carcinogenic potential of compounds is a crucial aspect in human hazard and risk 
assessment of chemicals. To date, the standard approach to assess carcinogenicity at a 
regulatory level is the 2-year bioassay in rodents (OECD TG 451, TG 453). 
Several in vitro alternatives have been developed for predicting carcinogenicity. Of these, the in 
vitro genotoxicity tests address only one mechanism involved in carcinogenicity, the induction 
of genetic damage. In contrast, in vitro Cell Transformation Assays (CTAs) have been shown to 
involve a multistage process that closely models some stages of in vivo carcinogenesis. 
The Bhas 42 CTA is a sensitive short-term system that has reduced associated cost and labor 
compared with those associated with the conventional BALB/c 3T3 CTA. The Bhas 42 cells were 
developed from the BALB/c 3T3 cells through the transfection with v-Ha-ras [Sasaki et al., 1988]. 
Using these cells Asada et al. [2005] generated a modified Bhas 42 CTA capable of detecting 
tumor-initiating activity as well as tumor-promoting activity of chemicals.  
This current protocol consists of two assay components, the initiation assay and the promotion 
assay, proposed to detect the tumor-initiating activity and the tumor-promoting activity of 
chemicals, respectively. A test chemical is positive in the Bhas 42 CTA if the chemical is positive 
in one of the two assays. Because of the increased sensitivity of cells to transformation, the 
assay duration has been reduced to 3 weeks (instead of 6 weeks in the BALB/c 3T3 CTA), and 
the assay scales such as the dish size, the dish number, the medium volume, the serum 
concentration in the cultures have been reduced. 
The Hatano Research Institute (HRI) undertook a research project financed by the New Energy 
and Industrial Technology Development Organization (NEDO, Japan) to characterize, evaluate, 
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refine and validate the Bhas 42 CTA. Under the project, the Bhas 42 CTA has been applied to 98 
chemicals including carcinogens and non-carcinogens, and it has been confirmed that its 
performance for the prediction of chemical carcinogenicity is superior or equivalent to those of 
conventional genotoxicity assays and the assay is capable of detecting Ames-negative and 
Ames-discordant carcinogens in addition to Ames-positive carcinogens [Sakai et al., 2010]. In 
the meantime, JaCVAM has submitted an SPSF for the development of a Test Guideline based 
on the Bhas 42 CTA to the OECD, which was added to the rolling work-plan in 2007. 
The above mentioned studies on the Bhas 42 CTA, development, improvement and application 
to 98 chemicals, were performed using 6-well plates (6-well method). Meanwhile, the Bhas 42 
CTA using 96-well microplates (96-well method) has been developed to be utilized for high 
throughput automated applications. The assay procedures are fundamentally the same 
between the 6-well and 96-well methods, except for the statistical methods used. 
Two validation studies on the Bhas 42 CTA, a validation study on the 6-well method [Sakai et al., 
2011] and a validation study on the 96-well method, were carried out under the NEDO project. 
EURL ECVAM requests ESAC advice on the latter two validation studies which were the JaCVAM- 
initiative. 
Given this background, the opinion of the ESAC should provide expert advice to EURL ECVAM on 
two studies that JaCVAM conducted in view of assessing whether the Bhas 42 CTA protocols (6-
well plates and 96-well plates) have been sufficiently validated. 
In providing this advice, ESAC is requested to take account of the information presented in the 
validation report and address also the suitability of the CTA assays/protocols in question to be 
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1. TYPE OF REQUEST 
Request Type Identify request ("YES") 
1. ESAC Peer Review of a Pre-validation Study or Validation 
Study 
YES 
If 1) applies please specify further: 
Prevalidation Study  
Prospective Validation Study YES 
The study addressed protocol standardisation, 
transferability, reproducibility and predictivity of 
the Bhas 42 CTA in view of establishing standardized 
protocols for future consistent use, e.g. through the 
development of OECD Test Guidelines for in vitro 
carcinogenicity testing.  
Retrospective Validation Study  
Validation Study based on Performance 
Standards 
 
2. Scientific Advice on a test method submitted to ECVAM 
for validation  
(e.g. the test method's biological relevance etc.) 
 
3. Other Scientific Advice  
(e.g. on test methods, me-too tests, performance standards, their 
use; on technical issues such as cell culturing, stem cells etc.) 
 
2. TITLE OF STUDY OR PROJECT FOR WHICH SCIENTIFIC ADVICE OF THE 
ESAC IS REQUESTED 
Validation study of Bhas 42 cell transformation assays for evaluation of carcinogenicity potential 
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3. BRIEF DESCRIPTION OF THE STUDY OR PROJECT 
1) Background to carcinogenicity testing and available alternative methods 
 
The carcinogenic potential of compounds is a crucial aspect in human hazard and risk assessment of 
chemicals. To date, the standard approach to assess carcinogenicity at a regulatory level is the 2-year 
bioassay in rodents (OECD TG 451, TG 453). 
Several in vitro alternatives have been developed for predicting carcinogenicity. Of these, the in vitro 
genotoxicity tests address only one mechanism involved in carcinogenicity, the induction of genetic 
damage. In contrast, in vitro Cell Transformation Assays (CTAs) have been shown to involve a 
multistage process that closely models some stages of in vivo carcinogenesis: CTAs can detect 
phenotypic changes of cultured cells as a result of exposure to test materials (i.e. chemicals, products 
etc.). These phenotypic/morphological changes are a result of the transformation of cultured cells 
which involves changes in cell behaviour and proliferation control (e.g. altered cell morphology, 
changed colony growth patterns and anchorage-independent growth). Moreover, transformed cells 
can evolve to be tumorigenic when injected in a suitable host. Importantly, CTAs are to date the only 
optimised tests that allow the detection of both genotoxic and non-genotoxic carcinogens. CTAs have 
been in use for about 40 years and a large amount of data was available. Taking advantage of this, 
the Organisation for Economic Cooperation and Development (OECD) finalised in 2007 a "Detailed 
Review Paper on Cell Transformation Assays for Detection of Chemical Carcinogens" [2007, Ref. 1] 
that focused on the capability of three CTAs (the Syrian hamster embryo cells (SHE), the BALB/c 3T3 
and the C3H10T1/2 assays) to predict rodent carcinogenicity. Recently, EURL-ECVAM conducted a 
prevalidation study of three CTAs using SHE cells at pH 6.7 and pH 7.0 and the BALB/c 3T3 mouse 
fibroblast cell line with the aim of assessing protocol standardisation, transferability, within- and 
between-laboratory reproducibility. This study was submitted to ESAC for Peer Review and EURL 
ECVAM subsequently issued a recommendation on the three CTAs [EURL-ECVAM recommendation 
and ESAC Opinion; Ref. 2]. Based on these activities, in April 2012 the OECD WNT agreed to proceed 
with the drafting of a Test Guideline for the SHE CTA. 
3) Bhas 42 CTA: Development, characteristics, two assay methods and validation 
The Bhas 42 CTA is a sensitive short-term system that has reduced associated cost and labor 
compared with those associated with the conventional BALB/c 3T3 CTA. The Bhas 42 cells were 
developed from the BALB/c 3T3 cells through the transfection with v-Ha-ras [Sasaki et al., 1988, Ref. 
3]. The Bhas 42 cells are transformed by known tumor promoters, including 12-O-
tetradecanoylphorbol-13-acetate (TPA), okadaic acid and lithocholic acid, without initiating 
treatment with a known tumor initiator such as 3-methylcholanthrene (MCA) [Omori et al., 2004, 
Ref. 4], and are presumed to be initiated toward transformation by the introduced ras sequence 
[Sasaki et al., 1990, Ref. 5]. Asada et al. generated a modified Bhas 42 CTA capable of detecting 
tumor-initiating activity as well as tumor-promoting activity of chemicals [2005, Ref. 6]. This current 
protocol consists of two assay components, the initiation assay and the promotion assay, to detect 
the tumor-initiating activity and the tumor-promoting activity of chemicals, respectively. A test 
chemical is positive in the Bhas 42 CTA if the chemical is positive in one of the two assays. Because of 
the increased sensitivity of cells to transformation, the assay duration has been reduced to 3 weeks 
(instead of 6 weeks in the BALB/c 3T3 CTA), and the assay scales such as the dish size, the dish 
number, the medium volume, the serum concentration in the cultures have been reduced. 
The Hatano Research Institute (HRI) undertook a research project financed by the New Energy and 
Industrial Technology Development Organization (NEDO, Japan) to characterize, evaluate, refine and 
validate the Bhas 42 CTA. Under the project, the Bhas 42 CTA has been applied to 98 chemicals 
including carcinogens and non-carcinogens, and it has been confirmed that its performance for the 
prediction of chemical carcinogenicity is superior or equivalent to those of conventional genotoxicity 
assays and the assay is capable of detecting Ames-negative and Ames-discordant carcinogens in 
addition to Ames-positive carcinogens [Sakai et al., 2010, Ref. 7]. In the meantime, JaCVAM has 
submitted an SPSF for the development of a Test Guideline based on the Bhas 42 CTA to the OECD, 
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which was added to the rolling work-plan in 2007. 
The above mentioned studies on the Bhas 42 CTA, development, improvement and application to 98 
chemicals, were performed using 6-well plates (6-well method). Meanwhile, the Bhas 42 CTA using 
96-well microplates (96-well method) has been developed to be utilized for high throughput 
automated applications. The assay procedures are fundamentally the same between the 6-well and 
96-well methods, except for the statistical methods used. 
Two validation studies on the Bhas 42 CTA, a validation study on the 6-well method [Sakai et al., 
2011, Ref. 8] and a validation study on the 96-well method, were carried out under the NEDO 
project. EURL ECVAM requests ESAC advice on the latter two validation studies which were the 
JaCVAM- initiative. 
4) Study objectives and design 
The study objective is to validate the Bhas 42 CTA in formal inter-laboratory studies in order to assess 
its transferability, the within- and between-laboratory reproducibility and the predictive capacity. 
The ultimate goal is to demonstrate the utility of the assay for adoption as an OECD Test Guideline 
and for use as a component of a test battery for the prediction of chemical carcinogenicity.  
With respect to the modular approach of validation [Hartung et al., 2004, Ref. 9], the study assessed 
information concerning module 1) test definition, module 2) within-laboratory reproducibility, 
module 3) transferability, module 4) between-laboratory reproducibility and 5) predictive capacity. 
The study addressed two protocols of Bhas 42 CTA, the 6-well method and the 96-well method. In 
the validation of the 6-well method, six laboratories joined in the study, twelve chemicals were 
examined, and each chemical was tested by three laboratories. In the validation of the 96-well 
method, four laboratories participated, the study was forwarded stepwise, and a total of 25 
chemicals were tested including duplicate chemicals between phases. In the assessment of 
predictivity, in-house data which were obtained by HRI in Japan and had been published [Sakai et al., 
2010, Ref. 7] were referred to in addition to the results of the validation study.  
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4. OBJECTIVES, QUESTIONS, TIMELINES 
4.1 OBJECTIVE 
Objective 
Why does EURL 
ECVAM require 
advice on the 
current issue? 
Given the background in Section 3, the opinion of the ESAC should provide expert 
advice to EURL ECVAM on two studies that JaCVAM conducted in view of assessing 
whether the Bhas 42 CTA protocols (6-well plates and 96-well plates) have been 
sufficiently validated. 
In providing this advice, ESAC is requested to take account of the information 
presented in the validation report and address also the suitability of the CTA 
assays/protocols in question to be used as a basis for the development of an OECD 
Test Guideline as foreseen by the OECD work plan. 
4.2 QUESTION(S) TO BE ADDRESSED 
Questions 
What are the 
questions and 
issues that should 
be addressed by 
the ESAC WG? 
The ESAC is requested to address the following three questions: 
1) to review whether the study of the Bhas 42 CTAs was conducted appropriately 
in view of the stated purpose, i.e. of assessing the CTA test method as a scientific 
valid method.  
In particular the following issues should be addressed: 
Clarity of the definition of the study objective.  
Appropriateness of the study design (e.g. chemical selection, number of chemicals 
used, number of laboratories, acceptance criteria). 
Appropriateness of the study execution (e.g. were there pre-defined acceptance 
criteria, were these respected? How were exceptions / deviations handled, e.g. 
retesting?). 
Appropriateness of the statistical analysis as used in the protocols and for 
analysing reproducibility and predictive capacity. 
2) to assess whether the conclusions as presented in the Study Report are justified 
by the information generated during the study. 
In particular the following issues should be addressed: 
Provide a qualitative discussion of the study results/deliverables achieved within 
the limits of this study: 
Clarity and completeness of the protocol(s). 
Within laboratory reproducibility 
Transferability (critical issues and how they were handled) 
Between-laboratory reproducibility 
Predictive capacity 
Evaluate to which extent the conclusions presented in the study report are 
justified by the study results and present the working group conclusions. 
3) to express its opinion whether the CTA protocols are well standardized and 
could indeed be recommended to serve as a basis for an OECD Test Guideline on in 
vitro carcinogenicity testing, in addition to: 
The similarity of the 6 and 96-well protocols. Please provide a recommendation 
whether they could be merged into one integrated protocol. 
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When does EURL 
ECVAM require 
the advice? 
urgency) prior to the next ESAC 
Request to be presented to ESAC at 
ESAC plenary meeting 
 
5. EURL ECVAM PROPOSALS ON HOW TO ADDRESS THE REQUEST 
WITHIN ESAC 





ESAC to address 
the request 
Does the advice 
require an ESAC 
working group, an 
ESAC rapporteur 
etc.? 
Structure(s) required Required according to EURL ECVAM? 
(YES/NO) 
ESAC Rapporteur  Yes 
ESAC Working Group Yes, Dr. Rodger Curren and Dr. Erwin Roggen 
Invited Experts Dr. David Lovell 
Dr. Edgar Rivedal 
Dr. Takeki Tsutsui 
If yes – list names and 
affiliations of suggested 
experts to be invited and 
specify whether these are 
member of the EEP 
 
If other than above :   
5.2 DELIVERABLES AS PROPOSED BY EURL ECVAM 
Deliverables 
What deliverables 
(other than the 




Title of deliverable other 
than ESAC opinion 
Required? No 
ESAC Rapporteur Report and 
draft opinion  
No 
ESAC Peer Review Report and 
draft opinion 
Yes 
If other than above :  
6. LIST OF DOCUMENTS TO BE MADE AVAILABLE TO THE ESAC 




1 VMT study report on Bhas 42 CTA YES 1. Bhas_Validation_Study_Report.pdf 
2 Supplier, catalogue number and lot 
number of test chemicals in the 6-
well method validation study. 
YES Annex_1_Ver _3_6-
Well_Chemicals_Supplier.pdf 
3 Protocol of Bhas42 CTA 6-well 
method (version 2) 
 Annex_2_6-Well_Protocol.pdf 
4 Photo Catalog for the Judgment of  Annex_3_Bhas_Foci_Catalog.pdf 
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Foci in the Bhas 42 CTA 
5 Results (raw data) Submitted from 
Laboratories in the Validation Study 
of 6-Well Method 
 Annex_4_Raw_Data_6-Well[1].pdf 
6 Supplier, catalogue number and lot 
number of test chemicals in the 96-
well method validation study  
 Annex_5_Ver _3_96-
Well_Chemicals_Supplier.pdf 
7 Protocol of Bhas42 CTA 96-well 




8 Protocol of Bhas42 CTA 96-well 
method (version 3) – phase 1 
 Annex_7_96-Well_Phase_I_Protocol-
3.pdf 
9 Protocol of Bhas42 CTA 96-well 
method (version 4) – phase 2 
 Annex_8_96-Well_Phase_II_Protocol-
3.pdf 
10 Results (raw data) Submitted from 
Laboratories In the Pre-validation 




11 Results (raw data) Submitted from 
Laboratories In the Phase I of 
Validation Study Of 96-Well Method 
 Annex_10_Raw_Data_96-
Well_Phase_I[1].pdf 
12 Results (raw data) Submitted from 
Laboratories In the Phase II of 
Validation Study of 96-Well Method 
 Annex_11_Raw_Data_96-
Well_Phase_II[1].pdf 
13 Recommended Protocol for the 




14 Transformation frequency of 
negative and positive controls 
 Annex_13_Transformation_Frequenc
y_Of_Controls.pdf 
15 Chemical properties and classes of 
12 coded test chemicals and 
positive controls for the 6-well 
method validation study 
 Annex_14_6-
Well_Chemical_Properties.pdf 
16 Chemical properties and classes of 
test chemicals for the pre-validation 
phase, phase I and phase II of 96-
well method validation study 
 Annex_15_96-
Well_Chemical_Properties.pdf 
17 Sakai, A. et al (2010) A Bhas 42 cell 
transformation assay on 98 
chemicals: The characteristics and 
performance for the prediction of 
chemical carcinogenicity. Mutation 
Research 702 (2010) 100–122. 
 Annex_16_Article_On_98_Chemicals.
pdf 
Note: Other documents that may be useful for conducting the peer review (e.g. manuscripts) 
are available at EURL ECVAM upon request. 
 
  




7. TERMS OF REFERENCE OF THE ESAC WORKING GROUP 
7.1 ESTABLISHMENT OF THE ESAC WORKING GROUP 
During its 36th meeting on 21 March 2012 the ESAC plenary unanimously decided to establish an 
ESAC Working Group charged with the detailed scientific review of a study on the Bhas 42 CTA. 
7.2 TITLE OF THE STUDY OR PROJECT 
Full title:  




Bhas 42 CTA 
7.3 MANDATE OF THE ESAC WG 
The EWG is requested to conduct a scientific peer review of the Bhas 42 CTA test method. The 
peer review needs to address the questions in Section 4.2 of this request to ESAC by EURL 
ECVAM. A general template for reporting is attached as Annex 1. 
7.4 REQUESTED DELIVERABLES OF THE ESAC WG 
The ESAC WG is requested to deliver to the chair of the ESAC the following two documents:  
Draft ESAC WG Report detailing its analyses and conclusions 
Draft ESAC Opinion outlining the key findings and recommendations 
The conclusions drawn in the report should be based preferably on consensus. If no consensus 
can be achieved, the draft Report and Opinion should clearly outline the differences in the 
appraisals and provide appropriate scientific justifications. 
 
7.5 PROPOSED TIMELINES OF THE ESAC WG 
The Secretariat has proposed timelines which should be agreed upon during the first 
Teleconference (Item 1 in the table): 
 
Item Proposed date/time Action Deliverable 
1 1-2 October 2012 Meeting of the EWG Develop the EWG Draft 
Report and Opinion 
2 6-7 November 2012 ESAC37 Deliver the final EWG 
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The carcinogenic potential of compounds is a crucial aspect in human hazard and risk assessment of substances. 
Among the various alternatives developed for carcinogenicity prediction, the cell transformation assays (CTAs) have 
been shown to closely model some key stages of the in vivo carcinogenesis process. Similar to previously validated in 
vitro CTAs, the CTA in Bhas 42 cells aims at predicting carcinogenic potential. Based on the results of a validation study 
coordinated by Hadano Research Institute (HRI) Food and Drug Safety Center (FDSC) and other published data, the 
Bhas 42 CTA protocol (including the 6-well and 96-well plate versions) was considered to be sufficiently standardised, 
transferable, reproducible between laboratories and relevant to support the identification of potential carcinogenicity of 
substances. Following independent scientific peer review by the EURL ECVAM’s Scientific Advisory Committee (ESAC) 
and having considered the input from regulators, stakeholders, international partners and the general public, EURL 
ECVAM concluded that the CTA in Bhas 42 cells shows promise for inclusion within weight of evidence or integrated 
testing strategy approaches to assess carcinogenic potential or to support chemical category formation and read-
across. Thus EURL ECVAM recommends that an OECD test Guideline be developed. In addition, further investigations on 
the capability of the assay to detect tumour promoters would provide useful information on mode of action of 






As the Commission’s in-house science service, the Joint Research Centre’s mission is to provide 
EU policies with independent, evidence-based scientific and technical support throughout the 
whole policy cycle. 
 
Working in close cooperation with policy Directorates-General, the JRC addresses key societal 
challenges while stimulating innovation through developing new standards, methods and tools, 
and sharing and transferring its know-how to the Member States and international community. 
 
Key policy areas include: environment and climate change; energy and transport; agriculture 
and food security; health and consumer protection; information society and digital agenda; 
safety and security including nuclear; all supported through a cross-cutting and multi-
disciplinary approach. 
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